Uniqure announces dosing of first patient in phase i/iia clinical trial of amt-191 for the treatment of fabry disease

Lexington, mass. and amsterdam, aug. 15, 2024 (globe newswire) -- uniqure n.v. (nasdaq: qure), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in a phase i/iia clinical trial of amt-191 for the treatment of fabry disease, a rare, inherited genetic disease. the phase i/iia study is a multi-center, open-label trial being conducted in the united states with two dose-escalating cohorts assessing the safety, tolerability and early signs of efficacy of amt-191 in individuals with fabry disease.
AMT Ratings Summary
AMT Quant Ranking